Skip to main content

Table 1 Patient characteristics

From: Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer

  Low-level TUBB3 expression High-level TUBB3 expression P
H-score 1-3 H-score 4-6
Age    
  < 56 32 (44.4) 40 (55.6) 0.105
  ≥ 56 37 (50.0) 37 (50.0)
Sex    
  Male 49 (47.1) 55 (52.9) 1
  Female 20 (47.6) 22 (52.4)
Location    
  GEJ-cardia 9 (56.3) 7 (43.8) 0.8
  Body 42 (45.7) 50 (54.3)
  Antrum 18 (47.4) 20 (52.6)
Differentiation    
  Well, moderately 15 (41.7) 21 (58.3) 0.45
  Poorly, signet ring cell 54 (49.1) 56 (509)
Lauren classification    
  Intestinal 41 (47.7) 45 (52.3) 0.211
  Diffuse 17( 39.5) 26 (60.5)
  Mixed 11 (64.7) 6 (35.3)
Disease status    
  Initial metastasis 41 (45.6) 49 (54.4) 0.614
  Recurrence after curative resection 28 (50.0) 28 (50.0)
Metastatic site    
  Liver    
  Yes 20 (48.8) 21 (51.2) 0.855
  No 49 (46.7) 56 (53.3)
  Peritoneum    
  Yes 35 (53.0) 31 (47.0) 0.245
  No 34 (42.5) 46 (57.5)
  Bone    
  Yes 5 (50.0) 5 (50.0) 1
  No 64 (47.1) 72 (52.9)
Chemotherapy response    
  CR + PR 34 (54.8) 28 (45.2) 0.133
  SD + PD 35 (41.7) 49 (58.3)
Chemotherapeutic regimen    
  Paclitaxel and cisplatin 58 (44.3) 73 (55.7) 0.053
  Docetaxel and cisplatin 11 (73.3) 4 (26.7)
No. of involved organs    
  1 41 (41.8) 57 (58.2) 0.107
  2 25 (61.0) 16 (39.0)
  ≥ 3 3 (42.9) 4 (57.1)
ERCC1 H-score    
  1-3 36 (52.9) 32 (47.1) 0.245
  4-6 33 (42.3) 45 (57.7)
  1. GEJ, gastrointestinal junction; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; TUBB3, class III β-tubulin; ERCC1, excision repair cross-complementation group 1.